7 completed. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 4 | Completed 4 |
Follow PLD: new trials by email Literature Review of PLD trials Research Report on PLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154 - Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Shattuck Labs, Inc. | 86 | 2022-08-18 | 2025-12-23 |
| A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. AZD7648, PLD - Advanced Malignancies | Phase 1 / Phase 2 | Completed | AstraZeneca | 30 | 2019-10-09 | 2024-02-06 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors TRK-950, Irinotecan, Leucovorin - Solid Tumor, Colorectal Cancer | Phase 1 | Completed | Toray Industries, Inc | 138 | 2019-04-26 | 2026-10-08 |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 53 | 2015-12-02 | 2022-10-10 |
| Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Melphalan, Prednisone, Cyclophosphamide - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Oncotherapeutics | 45 | 2014-09-01 | 2023-10-31 |
| Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer Farletuzumab, Carboplatin, and PLD - Epithelial Ovarian Cancer | Phase 1 | Completed | Morphotek | 15 | 2009-11-01 | 2014-07-17 |
| Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) Cyclophosphamide, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD) - Multiple Myeloma | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 58 | 2008-09-01 | 2014-01-20 |
Ovarian Neoplasms (4) · Carcinoma, Ovarian Epithelial (3) · Fallopian Tube Neoplasms (2) · Multiple Myeloma (2) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Melanoma (1) · Recurrence (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
AstraZeneca (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Ludwig Institute for Cancer Research (1) · Morphotek (1) · Oncotherapeutics (1) · Shattuck Labs, Inc. (1) · Toray Industries, Inc (1)
United States (7) · United Kingdom (2) · Canada (1) · France (1) · Spain (1) · Switzerland (1)
Bradley J Monk, MD (1) · Dr Timothy Yap (1) · George Coukos, MD, PhD (1) · James R Berenson, MD (1) · Melissa Alsina, M.D. (1) · Susan Weil, MD (1)
PMID 31851518, PMID 37082579, PMID 41951722
2018 (1)